In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Transkaryotic Therapies nets $124.58mm in private placement

Executive Summary

Transkaryotic Therapies (therapeutic proteins and gene therapy) has netted $124.58mm with the private placement of 3.3mm common shares at $40 each to institutional and accredited investors. The share price is an (pr)8.5% discount to the stocks 10-day trailing average of $43.70.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies